
Verismo Therapeutics licenses in vivo CAR T engineering technology from Stanford Medicine, while Pfizer licenses in vivo CAR-T programs from Starna Therapeutics.
Drug-delivery failures — not flawed science — are the hidden driver of late-stage trial failures.
The long, complex process that it takes to successfully bring a drug to market is one of the biggest issues mentioned by members of the pharmaceutical and biotech industries. From a business standpoint, investors are wary to spend money on a molecule only for it to take years to discover that it’s not a viable treatment.






